Document not yet available
ManualCOAMSDSKallikrein-2 (KLK2), a secreted serine protease of the peptidase S1-kallikrein subfamily, harbors a single peptidase S1 domain and is abundantly expressed in the human prostate. KLK2 cleaves Met-Lys and Arg-Ser bonds in kininogen to produce Lys-bradykinin, with preferential proteolysis of Arg-|-Xaa bonds in small-molecule substrates. Its selective release of kallidin (lysyl-bradykinin) from kininogen occurs via hydrolysis at Met-|-Xaa or Leu-|-Xaa positions. Serpins such as protein C inhibitor, antichymotrypsin and plasminogen inhibit KLK2. KLK2 is established as a biomarker for prostate cancer.
| Synonyms | KLK2, Kallikrein 2, KLK2A2, hGK-1, hK2 |
|---|---|
| Protein Construction ＆ Source | •(Uniprot: P20151-1) Recombinant Human KLK2 Protein is expressed from HEK293 cells with hFc(IgG1) tag at the N-terminus. It contains AA IIe 25 - Pro 261. •The protein has a predicted MW of 56 kDa. The protein migrates as 55-70 kD-a when calibrated against under reducing (R) condition (SDS-PAGE) due to glycosylation. |
| Endotoxin | < 0.1 EU per ug as determined by the LAL method. |
| Purity | > 95 % as determined by SDS-PAGE. |
| Concentration ＆ Formulation | •1.2 mg/mL•Filtered through a 0.22 μm filter, stored in 25 mM Sodium Citrate, 1x PBS, pH 7.4. |
| Transportation ＆ Storage | This product is shipped under low-temperature conditions. Avoid repeated freeze-thaw cycles during handling.•Protein solution can be stored at 2-8°C for 2-7 days.•Samples are stable for 3 months from date of receipt at -20℃ /-80℃.•Recommend to aliquot the protein into smaller quantities for optimal storage. |
| Target background | Kallikrein-2 (KLK2), a secreted serine protease of the peptidase S1-kallikrein subfamily, harbors a single peptidase S1 domain and is abundantly expressed in the human prostate. KLK2 cleaves Met-Lys and Arg-Ser bonds in kininogen to produce Lys-bradykinin, with preferential proteolysis of Arg-|-Xaa bonds in small-molecule substrates. Its selective release of kallidin (lysyl-bradykinin) from kininogen occurs via hydrolysis at Met-|-Xaa or Leu-|-Xaa positions. Serpins such as protein C inhibitor, antichymotrypsin and plasminogen inhibit KLK2. KLK2 is established as a biomarker for prostate cancer. |
|---|
For research use only. Not for use in diagnostic or therapeutic procedures.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
